Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care Ya-Chen Tina ShihShelley Fuld NassoS. Yousuf Zafar Editorial 02 February 2018 Pages: 259 - 261
Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions Paolo A. CortesiLucia S. D’AngiolellaLorenzo G. Mantovani Review Article 23 November 2017 Pages: 263 - 284
Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Bram L. T. RamaekersRobert WolffManuela A. Joore Review Article Open access 25 November 2017 Pages: 285 - 288
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Nigel FleemanAhmed AbdullaDaniel Palmer Review Article 24 November 2017 Pages: 289 - 299
Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review Lazaros AndronisIlias GoranitisRui Duarte Systematic Review 09 December 2017 Pages: 301 - 322
Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review Peter GhijbenYuanyuan GuSilva Zavarsek Systematic Review 09 November 2017 Pages: 323 - 340
A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis Shijie RenJonathan MintonMatt Stevenson Original Research Article Open access 28 October 2017 Pages: 341 - 347
Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis Rebekah Fong Soe KhioeChris SkedgelLeo Alexandre Original Research Article 05 December 2017 Pages: 349 - 358
Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies Amr MakadyArd van VeelenWim Goettsch Original Research Article Open access 06 December 2017 Pages: 359 - 368
Sensitivity of the Medication Possession Ratio to Modelling Decisions in Large Claims Databases Margret V. BjarnadottirDavid CzerwinskiEberechukwu Onukwugha Original Research Article 11 December 2017 Pages: 369 - 380
Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’ Amir AnsaripourCarin A. Uyl-de GrootW. Ken Redekop Letter to the Editor 09 February 2018 Pages: 381 - 382
Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran” Noga GershonYakir Berchenko Letter to the Editor 13 February 2018 Pages: 383 - 384
